BrainCheck vs Neurotrack (2026)
Two population oriented cognitive screens that both keep the AI light, split by depth of evidence against breadth of distribution. BrainCheck carries the stronger record: published validation with sensitivity and specificity figures reported honestly, the clearest reimbursement guidance in the category naming actual CPT codes, and a named Class II regulated component. Neurotrack is built for reach rather than depth: cloud based on any device, sized to drop into a Medicare Annual Wellness Visit, integrating with all major EHRs in weeks, with named health system customers and the only published SOC 2 attestation of the four. Two honest cautions on Neurotrack: it is FDA registered rather than cleared, and much of its long publication record predates the current product after it removed its original eye tracking technology. If your failure mode is validated accuracy and a billable path, start with BrainCheck. If your failure mode is screening a whole population inside existing workflows, start with Neurotrack, understanding registration is not clearance.
- The stronger published validation: a 99 participant study reporting at least 88 percent sensitivity and specificity for dementia, an r=0.77 MoCA correlation, and a 529 participant multi site study, with the weak numbers reported alongside the good ones, graded A on clinical evidence where Neurotrack grades B.
- The reimbursement path is published: specific CPT codes, time based minimums, and telehealth eligibility in an annually updated guide, graded A on commercial transparency where Neurotrack publishes no code level guidance and grades C.
- Scope is drawn clearly and the regulated component is named: BrainCheck Assess is a Class II device stated as the single FDA regulated component, and the product is prominently not a stand alone diagnostic, graded A on autonomy.
- Population scale deployment is the design: cloud based, runs on any device with no specialised hardware, sized to fit inside a Medicare Annual Wellness Visit, graded A on both deployment and setting coverage where BrainCheck grades B.
- The broadest distribution and interoperability in the category: integrates with all major EHRs deploying in weeks, feeding Annual Wellness Visit compliance and RADV documentation, graded A on interoperability where BrainCheck names two EHRs and grades B.
- The only published security attestation among the four: SOC 2 and HIPAA stated directly on the product, graded B on security certifications where BrainCheck has none located.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. BrainCheck and Neurotrack are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | BrainCheck | Neurotrack |
|---|---|---|
| Primary category | Clinical Decision Support | Clinical Decision Support |
| Founded | 2015 | 2012 |
| Headquarters | Austin, Texas, United States | Redwood City, California, United States |
| Website | braincheck.com | neurotrack.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards BrainCheck its top capability grade on several axes, including Autonomy and Oversight Model, Clinical and Operational Evidence and HIPAA and BAA Posture. Set against Neurotrack, BrainCheck grades higher on several axes, including Autonomy and Oversight Model, Clinical and Operational Evidence and HIPAA and BAA Posture. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Neurotrack its top capability grade on EHR and Interoperability Depth, Deployment Model and Data Residency and Setting and Specialty Coverage. Set against BrainCheck, Neurotrack grades higher on several axes, including AI Safety and PHI Stewardship, EHR and Interoperability Depth and Deployment Model and Data Residency. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose BrainCheck or Neurotrack?
On the axes where the AI Health Index separates them, BrainCheck grades higher on several axes, including Autonomy and Oversight Model, Clinical and Operational Evidence and HIPAA and BAA Posture, and Neurotrack grades higher on several axes, including AI Safety and PHI Stewardship, EHR and Interoperability Depth and Deployment Model and Data Residency. BrainCheck leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do BrainCheck and Neurotrack differ most?
The widest separation the AI Health Index records between BrainCheck and Neurotrack is on Commercial Transparency, where BrainCheck grades A and Neurotrack grades C. That axis sits in the Commercial group, so it should carry the most weight for a buyer whose binding constraint is contracting, scope and what the price actually covers.
Where do BrainCheck and Neurotrack grade the same?
The AI Health Index grades BrainCheck and Neurotrack the same on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have BrainCheck and Neurotrack not disclosed?
At the last review, at least one of BrainCheck and Neurotrack published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both sit at the low AI end of this category, graded C on AI centrality: both deliver standardised digital tests with automated scoring rather than a model deriving novel signal. The difference is evidence against distribution. BrainCheck's evidence is stronger and current, graded A; Neurotrack grades B because a substantial share of its 25 paper record derives from the eye tracking research lineage the company has since removed from its clinician products, so the published evidence and the shipping product are not fully aligned, and sensitivity figures for the current three minute test were not located.
On regulatory status BrainCheck is a Class II device graded B, while Neurotrack is FDA registered rather than cleared, a materially weaker position it describes accurately. Neurotrack's countervailing strengths are real: the widest distribution, the best interoperability, and the only SOC 2 disclosure in the category. Neither publishes pricing.